Alembic Pharmaceuticals announces USFDA Final Approval for Doxycycline Capsules, 40 mg

365Telugu.com online news,Mumbai,28^th June, 2024:Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Capsules, 40 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Oracea Capsules, 40 mg, of Galderma Laboratories, L.P. (Galderma).

Doxycycline capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Refer label for a detailed indication.

Doxycycline Capsules, 40 mg have an estimated market size of US$ 123 million for twelve months ending March 2024 according to IQVIA.

Alembic has a cumulative total of 205 ANDA approvals (179 final approvals and 26 tentative approvals) from USFDA.

Also read :JIO INTRODUCES NEW UNLIMITED PLANS

Also read :PVR INOX Limited EXPANDS FOOTPRINT IN HYDERABAD WITH ALL 4K LASER CINEMA

Also read :OPPO’s Reno12 Series sets a new AI benchmark

ఇదికూడా చదవండి: ఈ ప్రభుత్వ పథకం ద్వారా 70 ఏళ్లు పైబడిన వృద్ధులందరికీ ఉచిత చికిత్స

ఇదికూడా చదవండి: ఇస్రో గూఢచర్యం కేసులో ఐదుగురిపై చార్జిషీట్ దాఖలు చేసిన సీబీఐ